본문 바로가기
KERD
논문KCI 등재

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

초록

Background/Aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells. Methods: Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications. Results: Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The “rich metabolism” subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, wellto- moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatorymicroenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32–S37) mutations, and an immune-desert/excluded phenotype. The “glycolysis” subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis. Conclusions: The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.

Abstract

Background/Aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells. Methods: Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications. Results: Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The “rich metabolism” subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, wellto- moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatorymicroenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32–S37) mutations, and an immune-desert/excluded phenotype. The “glycolysis” subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis. Conclusions: The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.

참고문헌 (41)

관련 논문AI추천

Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision im munotherapy and TACE therapyBinghua Li, Decai Yu, Laizhu Zhang, Tianci Luo, Weiwei Hu, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implicationsHall Michael N., Park Sujin생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 Reply to correspondence on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”Eun Ji Jang, Pil Soo Sung대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial on “Molecular classifica tion of hepatocellular carcinoma based on zoned met abolic feature and oncogenic signaling pathway”Masatoshi Kudo, Naoshi Nishida, Tomoko Aoki대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma고혜용, 윤미진, 이미수연세대학교의과대학 · Yonsei Medical Journal2018 · 제59권 제10호Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-re sistant subtype with distinct molecular featuresBeodeul Kang, Chan Kim, Chansik An, Dahyeon Son, Da-Yeon Lee, Dong Jun Shin, Gae Hoon Jo, Gwangil Kim, Haeyoun Kang, Hannah Yang, Hong Jae Chon, Ho Yeong Lim, Hyeyeong Kim, Ilhwan Kim, Incheon Kang, Jung Sun Kim, Junho Park, Ju-Seog Lee, Sanghoon Jung, Seonjeong Woo, Sohyun Hwang, So Jung Kong, Sung Hwan Lee, Won Suk Lee, Woo Young Kwon, Youngsoo Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호

이 간행물의 다른 논문 (36건)